Fatal or nonfatal stroke · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Micro‐ to macroalbuminuria5 · people with diabetes and kidney disease
1 finding from 1 review
Micro‐ to normoalbuminuria6 · people with diabetes and kidney disease
It is very uncertain whether dual therapy (angiotensin‐converting‐enzyme inhibitors plus… changes micro‐ to normoalbuminuria6 compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Urinary protein or albumin excretion ‐ total albumin excretion at 6 months · People with proteinuria or microalbuminuria due to sickle cell disease
1 finding from 1 review
Creatinine level · People with proteinuria or microalbuminuria due to sickle cell disease
1 finding from 1 review
Electrolyte levels · People with proteinuria or microalbuminuria due to sickle cell disease
1 finding from 1 review
Blood pressure · People with proteinuria or microalbuminuria due to sickle cell disease
1 finding from 1 review
Hemoglobin concentration (g/dL) · People with proteinuria or microalbuminuria due to sickle cell disease
1 finding from 1 review
Adverse events or toxicity · People with proteinuria or microalbuminuria due to sickle cell disease
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in all‐cause death Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in cardiovascular death Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Doubling of SCr Median · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in doubling of SCr Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal stroke Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal myocardial infarction Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in micro‐ to macroalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
RR 0.97 [0.67, 1.42]
965 participants
Low
Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in micro‐ to normoalbuminuria Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
1 finding from 1 review
Death (all causes) · people with diabetes and kidney disease
Angiotensin receptor blockers (ARB) alone showed no clear difference in all‐cause death Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with diabetes and kidney disease
Angiotensin receptor blockers (ARB) alone showed no clear difference in cardiovascular death Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).
1 finding from 1 review
Doubling of SCr Median · people with diabetes and kidney disease
Angiotensin receptor blockers (ARB) alone showed no clear difference in doubling of SCr Median compared with angiotensin‐converting‐enzyme inhibitors plus ARB (low certainty).
1 finding from 1 review